<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511082</url>
  </required_header>
  <id_info>
    <org_study_id>252-07-801-01</org_study_id>
    <secondary_id>252-07-801-01</secondary_id>
    <nct_id>NCT00511082</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma</brief_title>
  <official_title>Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To investigate the safety and tolerability of OPB-31121 following repeated oral
           administration of OPB-31121 in patients Non-Hodgkin's Lymphoma(NHL) or Multiple
           Myeloma(MM)

        -  To determine the potential dose-limiting toxicities and maximum-tolerated dose in
           patients treated with OPB-31121

        -  To determine the pharmacokinetics and anti-tumor efficacy of OPB-31121 in patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a single-center,open-label,phase 1 dose-escalation study to assess
      the safety,tolerability,pharmacokinetics, and anti-tumor efficacy of OPB-31121 in patients
      with relapsed or refractory NHL or MM.

        -  To investigate the safety and tolerability of OPB-31121 following repeated oral
           administration of OPB-31121 in patients NHL or MM

        -  To determine the potential dose-limiting toxicities and maximum-tolerated dose in
           patients treated with OPB-31121

        -  To determine the pharmacokinetics and anti-tumor efficacy of OPB-31121 in patients
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1.Pharmacokinetic Endpoints 2.Efficacy Endpoints &amp; Response Criteria</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Non-Hodgkin's Lymphoma(NHL)</condition>
  <condition>Multiple Myeloma(MM)</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPB-31121</intervention_name>
    <description>Patients will receive OPB-31121 administered orally, once daily for 4 weeks.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have relapsed or refractory NHL histologically confirmed.

          -  Relapsed or refractory NHL or MM patients must have experienced treatment failure.

          -  Chinese patients aged 18 years or older at the time of giving informed consent.

          -  Performance status score of 0-2 according to the incriteria of he Eastern Cooperative
             Oncology Group(ECOG)

          -  Life expectancy of longer than 3 months.

          -  Patients must have adequate vital organ function.

          -  Patients are willing to comply with the visit schedules of the hospitalization and
             outpatient clinic.

          -  Patients with prior chemotherapy, immunotherapy, cytokines therapy, major surgery, and
             radiotherapy to the index lesion must have been completed for a minimum period of 4
             weeks and recovered from the related toxicity (NCI CTCAE grade 0 or 1) before
             registration.

          -  Patients with systemic corticosteroid therapy (&gt;10 mg prednisone or equivalent) must
             have been completed for a minimum of 1 weeks and recovered from the related toxicity
             (NCI CTCAE grade 0 or 1) before registration.

          -  Patients with prior stem cell transplantation must be at least 8 weeks and have
             recovered from the related toxicity (NCI CTCAE grade 0 or 1) before registration.

        Exclusion Criteria:

          -  Patients are receiving another investigational agent or who have received another
             investigational agent within 6 months.

          -  Patients are receiving concurrent chemotherapy, biologic agents, or radiotherapy.

          -  Patients are receiving concurrent administration of warfarin.

          -  NHL or MM patients who are candidates for autologous stem cell transplantation are
             excluded from the study.

          -  Patients with other primary malignancy except squamous or basal cell skin cancer or
             cervical cancer in situ.

          -  Patients with acute lymphoblastic lymphoma/leukaemia, POEMS syndrome or plasma cell
             leukaemia.

          -  Lymphoma patients with symptomatic CNS involvement.

          -  Patients with uncontrolled intercurrent illness.

          -  Known HIV-positive/AIDS patients.

          -  Female patients who are pregnant, lactating, or possibly pregnant, or who wish to
             become pregnant during the study period.

          -  Patients will not or are unable to use appropriate contraceptive methods during the
             study period and for at least 6 months after completion of the study

          -  Patients need to receive any of the following treatments or therapeutic agents during
             the study period:

               -  Anti-cancer drugs other than the study drug

               -  Systemic corticosteroid therapy (&gt;10 mg prednisone or equivalent)

               -  Radiotherapy as primary therapy

               -  Immunotherapy

               -  Surgical therapy

               -  CYP3A4 and CYP2C9 enzyme inducers or inhibitors,or substrates, and CYP2B6,
                  CYP2C8, and CYP2D6 substrates.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenny IK Lei, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, Prince of Wales Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shii Man, M.D &amp; Ph.D.</last_name>
    <phone>+86-10-85182966</phone>
    <phone_ext>8001</phone_ext>
    <email>mans@obri.otsuka.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Shatin, N.T.</city>
        <state>Hong Kong, SAR</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenny IK Lei, M.D</last_name>
      <phone>(852) 2632 2137</phone>
      <email>kennylei@cuhk.cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2007</study_first_submitted>
  <study_first_submitted_qc>August 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2007</study_first_posted>
  <last_update_submitted>July 1, 2008</last_update_submitted>
  <last_update_submitted_qc>July 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2008</last_update_posted>
  <responsible_party>
    <name_title>Otsuka Beijing Research Institute</name_title>
    <organization>Otsuka Beijing Research Institute</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>August 2, 2011</submitted>
    <returned>August 31, 2011</returned>
    <submitted>September 8, 2011</submitted>
    <returned>October 7, 2011</returned>
    <submitted>June 13, 2012</submitted>
    <submission_canceled>Unknown</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

